secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2021-11-19T23:59:59+00:00
Accession:  0001185185-21-001711
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC enters 5-year CEO employment agreement with Ram Mukunda; salary $360K
-------------------------------------------------------------------------

- Employment agreement effective November 18, 2021; initial 5-year term with automatic 12-month renewals.
- Annual base salary of $360,000; eligible for annual bonus and equity grants under 2018 Omnibus Incentive Plan.
- Severance: 1.5x avg total comp (non-CIC) paid over 18 months; 2.99x lump sum upon change-in-control.
- Post-termination non-compete for 12 months; must retain 35% of equity received during tenure.
- Perquisites include car allowance ($1,500/month lease), D&O insurance for 10 years post-termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518521001711/0001185185-21-001711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518521001711/indiaglob20211119_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-21-001711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer